<DOC>
	<DOC>NCT00928590</DOC>
	<brief_summary>The purpose of this study is to describe the long-term safety of a fixed combination product containing an alternative preservative, dosed once daily for 12 months, in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<criteria>Willing and able to sign an informed consent document. Openangle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator. Stable treatment of an IOPlowering medication. Other protocoldefined inclusion criteria may apply. Pregnant, breastfeeding, or not using adequate birth control. Bestcorrected visual acuity (BCVA) worse than 55 ETDRS letters. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>pseudoexfoliation</keyword>
	<keyword>pigment dispersion</keyword>
</DOC>